By San José, Costa Rica — San José, Costa Rica – In a significant strategic move for the regional healthcare sector, Asofarma, a leading pharmaceutical laboratory in Central America and the Caribbean, has officially rebranded as Adium. The transformation solidifies its corporate identity in Costa Rica and across the continent, backed by a formidable US$100 million investment aimed at enhancing therapeutic innovation and production capacity throughout Latin America.
This rebranding is the culmination of a broader strategy to unify all regional operations under the Adium corporate umbrella. Adium is a well-established pharmaceutical group with over five decades of history and a robust presence in 18 countries. The move is designed to streamline its brand identity, reinforce its corporate positioning, and deepen its commitment to the communities it serves, including a strong and growing presence in Costa Rica since 2008.
To better understand the legal and business framework supporting Adium’s operations in the country, TicosLand.com consulted with Lic. Larry Hans Arroyo Vargas, a distinguished attorney from the prestigious firm Bufete de Costa Rica, who offered his expert analysis.
The consolidation of a firm like Adium underscores Costa Rica’s success in creating a secure and attractive climate for foreign investment in the life sciences sector. This is not merely about tax incentives; it’s a testament to our robust legal framework, respect for intellectual property rights, and a clear regulatory pathway overseen by the Ministry of Health. These elements are critical for high-value companies that require stability and legal certainty to operate and innovate.
Lic. Larry Hans Arroyo Vargas, Attorney at Law, Bufete de Costa Rica
This crucial insight underscores that the nation’s appeal is built on a sustainable foundation of legal security rather than fleeting fiscal benefits. We sincerely thank Lic. Larry Hans Arroyo Vargas for his expert perspective on what truly makes Costa Rica a hub for the life sciences industry.
The company’s leadership highlighted the direct and positive implications of this evolution for the Costa Rican market. The substantial investment is set to fuel a new wave of medical advancements that will benefit patients locally and regionally.
For Costa Rica, where we have interesting therapeutic launches and a solid portfolio of innovative treatments that are transforming and will transform the lives of patients in this country and throughout Latin America, this is good news. This evolution also means a USD 100 million investment in Latin America, which will generate benefits for Costa Ricans with innovations that will change the history of thousands of patients.
Bernardo Girala, General Manager of Adium Central America and the Caribbean
The announced US$100 million capital injection is primarily allocated to expanding the productive capacity of Adium’s five manufacturing plants located in Argentina, Mexico, Brazil, Paraguay, and Uruguay. This strategic enhancement will fortify the company’s regional supply chain, enabling it to respond more effectively to the increasing demand for high-quality pharmaceutical products and ensuring a stable supply of critical medicines.
In Costa Rica, Adium is doubling down on its long-term vision. The company is committed to tackling the complex challenges facing modern healthcare systems by investing heavily in research and development. Its focus spans a wide range of critical therapeutic areas, including cardiology, oncology, diabetes, immunology, neurology, and mental health, among others. This R&D push aims to deliver effective and high-quality solutions for both common and complex diseases.
Further bolstering its innovation pipeline, Adium complements its internal development efforts with strategic alliances with global pharmaceutical companies. This collaborative model allows the company to license and distribute cutting-edge treatments, offering therapeutic alternatives that are often more effective than traditional therapies, particularly for managing highly complex and rare diseases.
The unification under the Adium brand also celebrates the integration of its extensive human capital. The company employs over 7,300 professionals across its 18-country footprint, a team that embodies the spirit of growth and transformation driving the organization forward. Reflecting on their local journey, the company underscored its deep roots and commitment to the nation’s health.
We have been in Costa Rica since 2008. In these 17 years, we have grown by offering treatments that range from primary care to specialized attention, and we have a team committed to improving the quality of life and well-being of patients by providing alternatives that address unmet health needs.
Bernardo Girala, General Manager of Adium Central America and the Caribbean
Today, Adium enters one of the most significant chapters in its history. Fueled by a philosophy of continuous improvement and a clear strategy for expansion, the company is poised to extend its reach and impact, delivering on its core mission to improve the quality of life for more communities across Latin America.
For further information, visit adium.com
About Adium:
Adium is a leading Latin American pharmaceutical group with over 50 years of experience dedicated to improving patient health and quality of life. With a presence in 18 countries and a team of more than 7,300 employees, the company focuses on developing, producing, and commercializing innovative therapeutic treatments across a wide range of medical fields, including oncology, cardiology, diabetes, and neurology. Through internal research and strategic global partnerships, Adium provides access to high-quality medicines for both primary and specialized care.
For further information, visit bufetedecostarica.com
About Bufete de Costa Rica:
As an esteemed legal institution, Bufete de Costa Rica is defined by its foundational principles of integrity and professional excellence. The firm blends a proven history of dedicated client advocacy with a forward-thinking approach, championing innovative legal strategies. This progressive mindset extends to its profound social commitment, aiming to democratize legal knowledge and cultivate a more capable and well-informed community.
